Attachments
Top line SOLARIO data presented at EBJIS
Subscription
Description
| Country | Sweden |
|---|---|
| List | Large Cap Stockholm |
| Sector | Health care |
| Industry | Medical technology |
Interested in the company’s key figures?
Analyze the company in Börsdata!
Who owns the company?
Find all ownership data in Holdings!
BONESUPPORT™, a leading company in orthobiologics for the management of bone injuries, today announces that the top line data from the SOLARIO trial, funded by the European Bone & Joint Infection Society (EBJIS) and the National Institute for Health and Care Research (NIHR UK), are expected to be presented on the opening day of the 42nd Annual Meeting of EBJIS in Barcelona from September 26th to 28th.
The SOLARIO* trial involves 500 adult patients with orthopedic infections who are followed for one year. The study's objective is to assess whether patients treated surgically with local antibiotic-eluting bone defect fillers, such as CERAMENT® G and CERAMENT® V, achieve similar outcomes when receiving either a short-term course of systemic antibiotics (up to seven days) or the conventional long-term regimen (at least four weeks of systemic antibiotics).
If the shorter systemic antibiotic regimen, with local antibiotics, proves to be non-inferior, it could offer significant advantages, including reduced antibiotic treatment duration and costs, fewer side effects, improved patient compliance, enhanced antimicrobial stewardship, with a decreased risk of antibiotic resistance. The results are expected to be published during next year.
*Dudareva M, Kumin M, Vach W, Kaier K, Ferguson J, McNally M, Scarborough M. Short or Long Antibiotic Regimes in Orthopaedics (SOLARIO): a randomized controlled open-label non-inferiority trial of duration of systemic antibiotics in adults with orthopaedic infection treated operatively with local antibiotic therapy. Trials 2019; 20: 693.